InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,495.52
(
0.45%
)
US TECH 100
18,346.40
(
0.00%
)
Dow Jones
40,736.96
(
-0.23%
)
Brent Oil
70.17
(
0.91%
)
Bitcoin
56,544.08
(
-1.94%
)
Post# of 253078
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120403
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 173645

Monday, 03/24/2014 2:39:07 PM

Monday, March 24, 2014 2:39:07 PM

Post# of 253078
ABBV/ENTA will present detailed results of three more phase-3 trials—SAPHIRE-1, SAPHIRE-2, and TURQUOISE-2—in oral presentations at EASL, April 10-12, 2014:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-data-presentations-090500374.html

TURQUOISE-2 should receive a lot of attention insofar as it’s the only large phase-3 trial with results for any HCV regimen in 100% cirrhotic patients.

Also at EASL is an oral presentation of a phase-2 trial called M12-999 that tested ABBV/ENTA’s 3-DAA regimen in liver-transplant recipients.

Note: Detailed results of PEARL-3 were presented at CROI in February (#msg-98175067), so PEARL-3 warrants only a poster presentation at EASL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up